Related Experiment Videos
[Different patterns of 123I-BMIPP myocardial accumulation in patients with type I and II CD36 deficiency]
1Department of Clinical Pharmacology, Niigata College of Pharmacy.
Insights
CD36 deficiency, a receptor involved in fatty acid metabolism, is more common in heart disease patients. Type I CD36 deficiency is linked to absent cardiac fatty acid uptake, suggesting a role in heart conditions.
Area of Science:
- Cardiology
- Molecular Biology
- Metabolic Diseases
Background:
- CD36 is a multifunctional glycoprotein receptor involved in binding various ligands, including long-chain fatty acids (LCFA), a key cardiac energy substrate.
- Dysregulation of LCFA metabolism is implicated in the pathogenesis of various cardiac diseases.
- Understanding CD36's role is crucial for elucidating mechanisms underlying heart conditions.
Observation:
- CD36 expression was analyzed in 200 heart disease patients (hypertrophic cardiomyopathy, dilated cardiomyopathy, myocardial infarction, angina pectoris).
- CD36 deficiency (Types I and II) was identified in 12% of patients, a higher prevalence than in control populations.
- 123I-beta-methyl-p-iodophenylpentadecanoic acid (BMIPP) myocardial accumulation was assessed to evaluate LCFA uptake.
Findings:
- Type I CD36 deficiency (absent expression on platelets and monocytes) was associated with a complete absence of cardiac BMIPP accumulation.
- Type II CD36 deficiency (present on monocytes, absent on platelets) showed focally reduced, but not absent, cardiac BMIPP accumulation.
- The study revealed a higher incidence of CD36 deficiency in patients with heart disease compared to controls.
Implications:
- Type I CD36 deficiency may play a significant role in LCFA metabolic disorders and specific cardiac conditions like hypertrophy.
- These findings highlight CD36 as a potential diagnostic or therapeutic target in managing heart diseases related to fatty acid metabolism.
- Further research into CD36 function could uncover novel insights into cardiac energy substrate utilization and disease progression.
Abstract:
The CD36 molecule is a multifunctional membrane type receptor glycoprotein that reacts with thrombospondin, collagen, oxidized LDL and long-chain fatty acids (LCFA). LCFA are one of the major cardiac energy substrates, hence LCFA metabolism may have an important role in cardiac diseases. In this study, we analyzed CD36 expression in 200 patients with heart diseases [44 patients with hypertrophic cardiomyopathy (HCM), 16 with dilated cardiomyopathy (DCM), 26 with old myocardial infarction (OMI), 55 with angina pectoris (AP) and 59 with other miscellaneous heart diseases] using a flow cytometer. 123I-beta-methyl-p-iodophenylpentadecanoic acid (BMIPP) myocardial accumulation was also examined in some patients. Eight patients (2 with HCM, 1 with DCM, 2 with OMI, and 3 with AP) were diagnosed as having type I CD36 deficiency (neither platelets nor monocytes expressed CD36). Sixteen patients (3 with HCM, 1 with DCM, 1 with OMI, 8 with AP, and 3 with other heart diseases) showed type II CD36 deficiency (monocytes expressed CD36 but platelets did not). In all 8 patients with type I CD36 deficiency, there was no BMIPP accumulation in the heart. However, in 13 patients with type II CD36 deficiency, focally reduced BMIPP accumulation was observed, but there were no patients without BMIPP accumulation. CD36 deficiency was observed in a higher proportion (12%) of patients with heart disease in this study than in a reported control study. Type I CD36 deficiency is associated with absence of BMIPP accumulation in the heart, hence it may have an important role in LCFA metabolic disorders and some types of cardiac hypertrophy as well as other heart diseases.